Vivani Medical, Inc.
NASDAQ:VANIMedical - Devices
+$0.02 today
- Market cap
- $94.71M
- Beta
- 3.29
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.33
Volume 0.18M
Average 0.24M
VANI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Vivani Medical, Inc.NASDAQ: VANI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $312K fell 10.9% year over year, behind the -10.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 33.2% from the prior quarter. Over 3 fiscal years it compounded at +4.6% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -10.9% toward the trailing-twelve-month pace of -10.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.48M USD
- Year-over-year change
- -7.8%
- 4-year CAGR
- -2.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.48M | -7.8% |
| FY2024 | 2024-12-31 | 1.61M | -13.6% |
| FY2023 | 2023-12-31 | 1.86M | +43.8% |
| FY2022 | 2022-12-31 | 1.3M | -22.3% |
| FY2021 | 2021-12-31 | 1.67M | — |
Stock-Based Compensation vs competitors
How VANI compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.0% is the 2nd highest of 7, against a peer median of -31.5%.
- Over three fiscal years its annual growth of +4.6% compares with a peer median of +10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$11.4M CAD | -21.5% | +28.8% | — | |
| LTM Mar 2026 | $7.93M USD | -41.7% | +10.8% | 11.0% | |
| LTM Mar 2026 | $2.5M USD | -41.5% | -35.9% | 16.3% | |
| LTM Mar 2026 | $2.28M USD | +4.3% | — | — | |
| LTM Mar 2026 | $1.45M USD | -10.0% | +4.6% | — | |
IMAImageneBio Inc | LTM Mar 2026 | $1.39M USD | -67.0% | +26.9% | — |
| LTM Mar 2026 | $1.02M USD | -11.2% | -15.5% | 974.3% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding VANI) | — | -31.5% | +10.8% | 13.6% | |
Competitors are the stored peer set for VANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.77M) | (13.89M) | (25.65M) | (23.49M) | (26.61M) |
| Depreciation & Amortization | 345K | 381K | 357K | 400K | 424K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.67M | 1.3M | 1.86M | 1.61M | 1.48M |
| Change in Working Capital | 436K | 338K | (1.29M) | 354K | 229K |
| Accounts Receivables | 0 | 0 | 0 | 0 | (401K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13K | (1.94M) | (602K) | 248K | (222K) |
| Other Working Capital | 423K | 2.28M | (691K) | 106K | 852K |
| Other Non-Cash Items | (627K) | (6.91M) | 1.03M | 336K | 152K |
| Operating Cash Flow | (10.95M) | (18.79M) | (23.7M) | (20.79M) | (24.32M) |
| Capital Expenditures | (572K) | (338K) | (887K) | (556K) | (1.17M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (572K) | (338K) | (887K) | (556K) | (1.17M) |
| Debt Repayment | 0 | 8M | 0 | 19.05M | 11K |
| Common Stock Issued | 11.62M | 16K | 133K | 18.82M | 23.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (28K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 55.37M | 0 | (18.82M) | 0 |
| Financing Cash Flow | 11.62M | 63.39M | 133K | 19.05M | 23.27M |
| Effect of Forex Changes | (1.1M) | (1K) | 3K | (14K) | 99K |
| Net Change in Cash | 97K | 44.26M | (24.45M) | (2.3M) | (2.12M) |
| Free Cash Flow | (11.52M) | (19.13M) | (24.59M) | (21.34M) | (25.49M) |
Vivani Medical, Inc.
NASDAQ:VANI
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.